The Latest Articles from Streetwise Reports


Co. Uses RNA Editing as Treatment for Rare Disease

Research Report
  ()
The firm plans to advance its alpha-1 antitrypsin deficiency program into the clinic next year, noted an H.C. Wainwright & Co. report.

Interim Results From Phase 2b Trial Are 'Encouraging'

Research Report
  ()
Data show the biotech's compound had a positive effect on several noninvasive measures, noted a ROTH Capital Partners report.

Biopharma Asks for Emergent Use in US of New COVID Drug

Research Report
  ()
The requested approval is specifically for critically ill patients, a population for which the U.S. Food and Drug Administration granted the therapeutic fast track status, noted an H.C. Wainwright & Co. report.

Opportunity for Investors Found in Psychedelics Space

Research Report
  ()
Treatment of alcohol use disorder with psychedelics plus therapy is effective, according to existing data, and the potential global market is large, noted an H.C. Wainwright & Co. report.
Tags:  Psychedelics

US Biotech Firm Keeps Growing Revenue

Research Report
  ()
Revenue last quarter was strong, and management expects to increase revenue 20% this fiscal year, noted a ROTH Capital Partners report.

Co.'s Clinical Program in HPV+ Cancers Gives It a Buy Rating

Research Report
  ()
To fund continued development of its lead immunotherapy candidate, the U.S.-based biopharma recently completed a $35 million debt financing agreement, noted an H.C. Wainwright & Co. report.

Analyst Says Buy Before Biotech Co.'s Clinical Trials

Research Report
  ()
Argenx SE has "several upcoming catalysts," noted a Wedbush report.

Telemedicine Co. Says It's Set To Thrive in Post-Pandemic World

  ()
The pandemic changed the way many people get their basic healthcare, giving a big opening to telemedicine companies like Reliq Health Technologies Inc.

Important Catalyst Expected Soon for Cancer Drug Co.

Research Report
  ()
The biopharma should announce initial clinical trial data on its lead small molecule candidate by year-end, noted a Wedbush report.

Dermatology Co.'s Target Price Much Higher Than Current

Research Report
  ()
The biopharma's strategic marketing campaign "should continue growing U.S. sales to current and new customers," noted a ROTH Capital Partners report.

Second Trial of New Eczema Drug To Commence in Q4/22

Research Report
  ()
The purpose behind this complementary study is to potentially expand the treatment's target patient population, noted an H.C. Wainwright & Co. report.

Price Target on US Biopharma Co. Boosted by $15

Research Report
  ()
The increase came after positive clinical trial results on one of its lead drug candidates differentiating it from a competitor, noted a BTIG report.

New Drug Shown To Help Patients With Desmoid Tumors

Research Report
  ()
This oral gamma-secretase inhibitor met the primary and secondary endpoints in a Phase 3 clinical trial, noted a Wedbush report.

Several Trials of Co.'s Fluid Pump To Read Out This Year

Research Report
  ()
Positive topline data could boost the share price of this Swiss medical device firm, noted an H.C. Wainwright & Co. report.

Co. Advancing Drug Class With Broad Potential

Research Report
  ()
This developer of C1q-targeting therapeutics, with a catalyst-rich 18 months ahead, warrants analyst coverage, noted a BTIG report.

Expert Says Life Science Co.'s Technical Setup Is 'Exceptionally Positive and Keeps Getting Better'

Contributed Opinion
  ()
Expert Clive Maund reviews the 6-month and 15-month charts for Awakn Life Sciences Corp. to explain why he thinks this company's technical setup is exceptionally positive.

Biotech Co.'s Target Six Times Current Price

Research Report
  ()
One Phase 2 clinical trial showing LSD reduced symptoms of anxiety bodes well for other studies of LSD in this indication. In light of this, Oppenheimer & Co. gave this biotech company a target price that is over six times its current share price.
Tags:  Psychedelics

Healthcare Co.'s To Develop Fast-Dissolving MDMA Tablet

  ()
One biopharma co. is teaming with a much larger pharmaceutical company to develop a fast-dissolving oral tablet to deliver MDMA to patients with Alcohol Use Disorder. Find out why developing an oral tablet could benefit the company in the long run.

Analyst Says Biopharma's New Inhaled Antifungal Drug Shows Promise

Research Report
  ()
Trial results are expected later this month, but anecdotal data available now suggest the findings should be positive, noted a ROTH Capital Partners report.

Showing Results: 1 to 25 of 181 Next

Get Our Streetwise Reports Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe

More Experts